

# Immune Response Against SARS-CoV-2

Angela Stufano <sup>1,†</sup> , Valentina Schino <sup>1,\*,†</sup>  and Guglielmo Lucchese <sup>2,3</sup> 

<sup>1</sup> Interdisciplinary Department of Medicine, University of Bari Aldo Moro, 70124 Bari, Italy; angela.stufano@uniba.it

<sup>2</sup> Department of Experimental Medicine, University of Salento, Via Lecce-Monteroni, 73047 Lecce, Italy; guglielmo.lucchese@unisalento.it

<sup>3</sup> Department of Neurology, University Medicine Greifswald, Ferdinand-Sauerbruch-Straße, 17475 Greifswald, Germany

\* Correspondence: valentina.schino@uniba.it

† These authors contributed equally to this work.

The immune response to SARS-CoV-2 infection is highly complex, involving a dynamic interplay between the innate and adaptive immune systems. Understanding this interplay is crucial for deciphering the varying disease outcomes, from mild to severe COVID-19. This editorial provides a concise overview of recent developments in the field, identifies the key gaps in knowledge addressed by the Special Issue, and outlines future research directions.

SARS-CoV-2 initially triggers an innate immune response through pattern recognition receptors (PRRs), which detect viral proteins and RNA, leading to the release of key pro-inflammatory cytokines such as interleukin-6 (IL-6), tumor necrosis factor alpha (TNF $\alpha$ ), and type I and III interferons (IFNs) [1,2]. However, the virus employs various strategies to evade this response, including inhibiting interferon signaling, impairing IFN release, and suppressing cytokine production. These mechanisms can contribute to severe disease outcomes, such as cytokine storms [3].

The adaptive immune response is critical, with antigen-presenting cells (APCs) presenting viral antigens to T and B cells. This interaction results in the production of virus-specific antibodies and the activation of cytotoxic T cells. CD4<sup>+</sup> T helper cells facilitate B cell differentiation into antibody-producing plasma cells, while CD8<sup>+</sup> cytotoxic T cells directly target and eliminate infected cells. Yet, SARS-CoV-2 has evolved mechanisms—such as reduced MHC-I expression and immune cell exhaustion—that impair long-lasting immunity and immune memory [4,5]. Variants of the virus, like Omicron, have shown reduced sensitivity to certain immune responses, which affects the efficacy of immunity from vaccines and monoclonal antibodies [6].

The link between SARS-CoV-2 infection and autoimmunity is particularly concerning. Post-infection, individuals are at an increased risk of developing systemic autoimmune diseases and long-term neurological symptoms. This is thought to result from immune dysregulation, including the production of autoantibodies targeting various tissues, such as the brain and nervous system [7,8]. These autoantibodies, possibly triggered by molecular mimicry, contribute to severe disease and lingering complications like memory deficits, dysautonomia, and chronic pain [8–10]. Early detection and targeted therapeutic strategies are crucial to managing these long-term consequences of COVID-19.

Managing severe symptoms and long COVID often involves therapeutic interventions to modulate the inflammatory response. Anti-inflammatory drugs like dexamethasone and IL-6 inhibitors (e.g., tocilizumab) help reduce cytokine storms [7]. Precision medicine and personalized treatments have proven beneficial for managing long COVID, a chronic condition characterized by persistent inflammation and immune dysregulation [11].

The findings from studies in this Special Issue underscore the multifaceted nature of the immune response to SARS-CoV-2. They highlight its implications for vaccine development, therapeutic strategies, and long-term management plans for both acute COVID-19



**Citation:** Stufano, A.; Schino, V.; Lucchese, G. Immune Response Against SARS-CoV-2. *Vaccines* **2024**, *12*, 1390. <https://doi.org/10.3390/vaccines12121390>

Received: 2 December 2024

Revised: 8 December 2024

Accepted: 10 December 2024

Published: 11 December 2024



**Copyright:** © 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<https://creativecommons.org/licenses/by/4.0/>).

and long COVID. For instance, Li et al. investigated immunity persistence post-vaccination, demonstrating the importance of booster doses in regions with high incidence of Omicron. Zalewska et al. explored immune responses in individuals receiving a heterologous ChAdOx1/BNT162b2 booster, noting enhanced antibody titers and IFN- $\gamma$  responses. Kibler et al. reported on a novel intranasal vaccine, which offered full protection against a lethal challenge with a heavily mutated strain in mice, highlighting the potential for mucosal immunity to combat SARS-CoV-2 variants. Vega-Magaña and colleagues examined T-cell responses in vaccinated individuals, revealing a decline in neutralizing antibodies over six months post-vaccination, which emphasizes the role of cellular immunity alongside humoral responses. Pourmasumi et al. reviewed the impact of SARS-CoV-2 on male fertility, discussing the alterations in sperm parameters post-infection, while Hajissa et al. reviewed SARS-CoV-2 antibodies' role in diagnostics and vaccine development. Karimabad et al. explored chemokines in the immune response and pathogenesis of COVID-19, suggesting their potential as therapeutic targets and markers for vaccine-induced immunity.

Each study in this collection provides unique insights into various aspects of COVID-19 immunity, vaccine efficacy, and broader health impacts. These findings are crucial for understanding pandemic management and immunological preventive approaches for severe disease and long-term sequelae. The complexity of the immune response to SARS-CoV-2 highlights the need for a multifaceted public health approach that integrates prevention, acute care, and chronic disease management. Future research should focus on elucidating the precise mechanisms of immune evasion by SARS-CoV-2, optimizing vaccine strategies to enhance long-lasting immunity, and developing therapies to prevent and manage long COVID. These efforts will be critical for addressing the ongoing challenges posed by the COVID-19 pandemic.

In summary, the immune response to SARS-CoV-2 is highly complex, involving both innate and adaptive immunity, and shaped by the virus's immune evasion strategies. The contributions to this Special Issue provide a deeper understanding of this evolving relationship, guiding vaccine development, therapeutic strategies, and long-term management plans for both acute COVID-19 and long COVID. These insights emphasize the importance of a holistic public health approach to managing the COVID-19 pandemic, with a focus on both prevention and treatment. Future research must continue to explore the dynamics of SARS-CoV-2 immunity and the implications for public health policy and clinical practice.

**Funding:** This research received no external funding.

**Conflicts of Interest:** The authors declare no conflicts of interest. The authors alone are responsible for the views expressed in this publication and they do not necessarily represent the views, decisions or policies of their institutions.

#### List of Contributions:

1. Li, J.; Xie, H.; Chen, W.; Chen, M.; Bai, S.; Zhao, W.; Zhou, T.; Gao, P.; Zhang, L.; Wang, Q.; et al. Immune persistence against SARS-CoV-2 after primary and booster immunization in humans: A large-scale prospective cohort study. *Vaccines* **2022**, *10*, 1677. <https://doi.org/10.3390/vaccines10101677>.
2. Zalewska, M.; Fus, W.; Konka, A.; Wystyrk, K.; Bochenek, A.; Botor, H.; Fronczek, M.; Zembala-John, J.; Adamek, B. An immune response to heterologous ChAdOx1/BNT162b2 vaccination against COVID-19: Evaluation of the anti-RBD specific IgG antibodies titers and interferon gamma release assay (IGRA) test results. *Vaccines* **2022**, *10*, 1546. <https://doi.org/10.3390/vaccines10091546>.
3. Kibler, K.V.; Szczerba, M.; Lake, D.; Roeder, A.J.; Rahman, M.; Hogue, B.G.; Wong, L.Y.; Perlman, S.; Li, Y.; Jacobs, B.L. Intranasal immunization with a vaccinia virus vaccine vector expressing pre-fusion stabilized SARS-CoV-2 spike fully protected mice against lethal challenge with the heavily mutated mouse-adapted SARS2-N501YMA30 strain of SARS-CoV-2. *Vaccines* **2022**, *10*, 1172. <https://doi.org/10.3390/vaccines10081172>.

4. Vega-Magaña, N.; Muñoz-Valle, J.F.; Peña-Rodríguez, M.; Viera-Segura, O.; Pereira-Suárez, A.L.; Hernández-Bello, J.; García-Chagollan, M. Specific T-cell immune response to SARS-CoV-2 spike protein over time in naïve and SARS-CoV-2 previously infected subjects vaccinated with BTN162b2. *Vaccines* **2022**, *10*, 1117. <https://doi.org/10.3390/vaccines10071117>.
5. Pourmasumi, S.; Nazari, A.; Ahmadi, Z.; Kouni, S.N.; de Gregorio, C.; Koniari, I.; Dousdampanis, P.; Mplani, V.; Plotas, P.; Assimakopoulos, S.; et al. The effect of long COVID-19 infection and vaccination on male fertility: A narrative review. *Vaccines* **2022**, *10*, 1982. <https://doi.org/10.3390/vaccines10121982>.
6. Hajissa, K.; Mussa, A.; Karobari, M.I.; Abbas, M.A.; Ibrahim, I.K.; Assiry, A.A.; Iqbal, A.; Alhumaid, S.; Mutair, A.A.; Rabaan, A.A.; et al. The SARS-CoV-2 antibodies, their diagnostic utility, and their potential for vaccine development. *Vaccines* **2022**, *10*, 1346. <https://doi.org/10.3390/vaccines10081346>.
7. Karimabad, M.N.; Hassanshahi, G.; Kounis, N.G.; Mplani, V.; Roditis, P.; Gogos, C.; Lagadinou, M.; Assimakopoulos, S.F.; Dousdampanis, P.; Koniari, I. The chemokines CXCL1, CXCL2 and CXCL3 in the pathogenesis of COVID-19 disease and as surrogates of vaccine-induced innate and adaptive protective responses. *Vaccines* **2022**, *10*, 1299. <https://doi.org/10.3390/vaccines10081299>.

## References

1. Maison, D.P.; Deng, Y.; Gerschenson, M. SARS-CoV-2 and the host-immune response. *Front. Immunol.* **2023**, *14*, 1195871. [[CrossRef](#)] [[PubMed](#)]
2. Zheng, M.; Karki, R.; Williams, E.P.; Yang, D.; Fitzpatrick, E.; Vogel, P.; Jonsson, C.B.; Kanneganti, T.-D. TLR2 senses the SARS-CoV-2 envelope protein to produce inflammatory cytokines. *Nat. Immunol.* **2021**, *22*, 829–838. [[CrossRef](#)] [[PubMed](#)]
3. Taefehshokr, N.; Taefehshokr, S.; Hemmat, N.; Heit, B. COVID-19: Perspectives on innate immune evasion. *Front. Immunol.* **2020**, *11*, 580641. [[CrossRef](#)] [[PubMed](#)]
4. Zhang, Y.; Chen, Y.; Li, Y.; Huang, F.; Luo, B.; Yuan, Y.; Xia, B.; Ma, X.; Yanga, T.; Yua, F.; et al. The ORF8 protein of SARS-CoV-2 mediates immune evasion through down-regulating MHC-I. *Proc. Natl. Acad. Sci. USA* **2021**, *118*, e2024202118. [[CrossRef](#)] [[PubMed](#)]
5. Zheng, M.; Gao, Y.; Wang, G.; Song, G.; Liu, S.; Sun, D.; Xu, Y.; Tian, Z. Functional exhaustion of antiviral lymphocytes in COVID-19 patients. *Cell. Mol. Immunol.* **2020**, *17*, 533–535. [[CrossRef](#)] [[PubMed](#)]
6. Sievers, B.L.; Cheng, M.T.K.; Csiba, K.; Meng, B.; Gupta, R.K. SARS-CoV-2 and innate immunity: The good, the bad, and the “goldilocks”. *Cell. Mol. Immunol.* **2024**, *21*, 171–183. [[CrossRef](#)] [[PubMed](#)]
7. Sharma, C.; Bayry, J. High risk of autoimmune diseases after COVID-19. *Nat. Rev. Rheumatol.* **2023**, *19*, 399–400. [[CrossRef](#)] [[PubMed](#)]
8. De Sá, K.S.G.; Silva, J.; Bayarri-Olmos, R.; Brinda, R.; Constable, R.A.R.; Colom Diaz, P.A.; Kwon, D.-I.; Rodrigues, G.; Li, W.; Baker, C.; et al. A causal link between autoantibodies and neurological symptoms in long COVID. *medRxiv* **2024**. [[CrossRef](#)]
9. Lucchese, G.; Vogelgesang, A.; Stufano, A.; Flöel, A. Impact of COVID-19 on the brain: Antibodies against brain stem antigens. *Elsevier* **2024**, *33*, 385–391.
10. Lucchese, G.; Vogelgesang, A.; Boesl, F.; Raafat, D.; Holtfreter, S.; Bröker, B.M.; Stufano, A.; Fleischmann, R.; Prüss, H.; Franke, C.; et al. Anti-neuronal antibodies against brainstem antigens are associated with COVID-19. *eBioMedicine* **2022**, *83*, 104211. [[CrossRef](#)] [[PubMed](#)]
11. Guo, Z.Y.; Tang, Y.Q.; Zhang, Z.B.; Liu, J.; Zhuang, Y.X.; Li, T. COVID-19: From immune response to clinical intervention. *Precis. Clin. Med.* **2024**, *7*, pbae015. [[CrossRef](#)] [[PubMed](#)]

**Disclaimer/Publisher’s Note:** The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.